WESTBOROUGH, Mass.,
Jan. 6, 2014 /PRNewswire/ -- RXi
Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology company
focused on discovering, developing and commercializing innovative
therapies addressing major unmet medical needs using RNA-targeted
technologies, today announced that the Company's President and
Chief Executive Officer, Dr. Geert
Cauwenbergh, will present at the Biotech Showcase™ 2014
conference on Tuesday, January 14,
2014 at 9:30AM PST. Dr.
Cauwenbergh will discuss the development of RXI-109, a
self-delivering RNAi compound designed to reduce dermal scarring,
as well as business development opportunities with RXi's sd‑rxRNA®
technology platform.
(Logo:
http://photos.prnewswire.com/prnh/20130917/NE80755LOGO)
A live webcast of the presentation will be available on the
"Investors" section of the Company's website,
www.rxipharma.com. A replay of the presentation will be
available 90 days.
Co-produced by Demy-Colton Life Science Advisors and EBD Group,
Biotech Showcase is an investor and partnering conference devoted
to providing private and public biotechnology and life sciences
companies an opportunity to present to, and meet with, investors
and pharmaceutical executives during the course of one of the
industry's largest annual healthcare investor conferences. Now in
its sixth year, Biotech Showcase is expected to attract upwards of
1,500 attendees.
The Biotech Showcase™ 2014 Conference will take place
January 13-15, 2014 at the Parc 55
Wyndham San Francisco Union Square Hotel, California. To schedule a meeting with RXi
Management at this conference, please contact Tamara McGrillen at tmcgrillen@rxipharma.com or
via phone 508-929-3646.
About RXi Pharmaceuticals Corporation
RXi Pharmaceuticals Corporation (OTCQX: RXII) is a biotechnology
company focused on discovering, developing and commercializing
innovative therapies based on its proprietary, self-delivering RNAi
platform. Therapeutics that use RNA interference, or "RNAi," have
great promise because of their ability to down-regulate the
expression of a specific gene that may be over-expressed in a
disease condition. Building on the pioneering work of scientific
founder and Nobel Laureate Dr. Craig
Mello, a member of the RXi Scientific Advisory Board, RXi's
first RNAi product candidate, RXI‑109, targets connective tissue
growth factor (CTGF) to reduce dermal scarring (fibrosis), entered
into human clinical trials in June 2012. For more
information, please visit www.rxipharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Such statements include, but are not limited to, statements
about future expectations, planned and future development of RXi
Pharmaceuticals Corporation's products and technologies.
Forward-looking statements about expectations and development plans
of RXi's products involve significant risks, and uncertainties:
risks that RXi may not be able to successfully develop its
candidates, or that development of RNAi-based therapeutics may be
delayed or not proceed as planned, or that we may not develop any
RNAi-based product; risks that the development process for our
product candidates may be delayed, risks related to development and
commercialization of products by our competitors, risks related to
our ability to control timing and terms of collaborations with
third parties, and the possibility that other companies or
organizations may assert patent rights preventing us from
developing our products. Actual results may differ from those
contemplated by these forward-looking statements. RXi does not
undertake to update forward-looking statements to reflect a change
in its views, events or circumstances that occur after the date of
this release.
Contacts
RXi Pharmaceuticals Corporation
Tamara McGrillen, 508-929-3646
tmcgrillen@rxipharma.com
SOURCE RXi Pharmaceuticals Corporation